Systasy Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Systasy Bioscience is a private German biotech firm that has developed a proprietary, breakthrough DNA barcoding technology for single-cell transcriptomics. Its platform enables highly multiplexed analysis of hundreds of pathological processes simultaneously, aiming to de-risk drug discovery by connecting compound activity to patient-specific data. The company operates as a technology provider and service partner for pharmaceutical companies, focusing on applications in pathway-based drug discovery, human disease models, and viral vector development for gene therapy. Key collaborations with entities like Ono Pharmaceutical and Evogene validate its platform's potential.

Genetics & GenomicsDiagnostics

Technology Platform

Proprietary DNA barcoding technology for highly multiplexed transcriptomic analysis at the single-cell level, integrated with patient-derived disease models for pathway-based drug discovery and safety profiling.

Opportunities

The rapidly growing markets for single-cell analysis and outsourced drug discovery services present a significant opportunity.

Systasy's unique platform for multiplexed pathway analysis directly addresses the pharmaceutical industry's critical need to reduce clinical failure rates, positioning it as a valuable derisking partner.

Expansion into new therapeutic areas and further validation through successful partner drug programs could dramatically increase its value.

Risk Factors

Key risks include competition from established genomics and CRO companies, dependency on a partnership-driven revenue model which is subject to deal flow fluctuations, and the need for ongoing scientific validation to prove its platform meaningfully improves drug success rates.

Protecting its core intellectual property is also paramount.

Competitive Landscape

Systasy competes in the single-cell genomics and specialized drug discovery CRO space. Direct competitors include large tools companies like 10x Genomics (for single-cell analysis) and contract research organizations offering phenotypic screening services. Its differentiation lies in the combination of its proprietary multiplexed barcoding, pathway-focused analysis, and integration with patient-derived models.

More companies in Diagnostics & Precision Medicine →More companies in Germany →